Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second ophthalmology program where clinical activity was predicted by tra
… ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer LEIDEN, the Netherlands, March … Strategy Officer. Dr. Rodman has had a long career in drugdevelopment including leadership roles in translational …
… held on April 8 - 10 in Monte Carlo, Monaco. World Orphan Drug Congress USA On Thursday, April 26, 2018 at 5:20 pm ET, … companies are ramping up innovation to boost orphan drugdevelopment and patient centricity’ during the World …
